☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
NLRP3 Inhibitors
Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B
April 1, 2019
Genentech Acquires Jecure Therapeutics for its Preclinical Stage NLRP3 inhibitors
November 29, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.
